MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, VRCA had $5,701K increase in cash & cash equivalents over the period. $9,685K in free cash flow.

Cash Flow Overview

Change in Cash
$5,701K
Free Cash flow
$9,685K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Total revenue
30,485 -
Selling, general and administrative
27,103 -
Research and development
6,335 -
Cost of revenue
2,040 -
Other segment items
4,819 -
Net loss
-9,812 -
Depreciation expense
-100
Stock-based compensation
718 1,914
Depreciation expense
19 100
Non-cash interest expense
716 1,359
Loss on disposal of fixed assets
-68 -178
Net loss
--9,538
Loss on termination of financing lease
1 -4
Amortization of operating lease right-of-use asset
74 146
Amortization of finance lease right-of-use asset
87 165
Non-cash accretion of r&d funding liability
375 -
Change in fair value of derivative liability
34 852
Prepaid expenses and other assets
2,094 -818
Collaboration receivable, billed and unbilled
-7,896 8,149
Inventory
-218 59
Accounts payable
-736 425
Deferred revenue
1,564 481
Accounts receivable
-2,146 9,145
Accrued expenses and other current liabilities
-501 -410
Operating lease liability
-79 -154
Net cash used in operating activities
9,685 -22,721
Purchases of property and equipment
0 0
Net cash used in investing activities
0 0
Proceeds from exercise of stock options
0 0
Payment of debt amendment fees
0 0
Repayment of debt
3,890 8,029
Repayment of finance lease
94 183
Payment of equity issuance costs
0 -
Net cash used in financing activities
-3,984 -8,212
Net decrease in cash and cash equivalents
5,701 -30,933
Cash and cash equivalents at beginning of period
46,329 -
Cash and cash equivalents at end of period
21,097 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Verrica Pharmaceuticals Inc. (VRCA)

Verrica Pharmaceuticals Inc. (VRCA)